XEOS wants to tackle the limitations of today’s available imaging techniques applied in surgical oncology, by leveraging the power of molecular imaging intra-operatively.
Founded in 2019 in Ghent, Belgium, XEOS is an expert in specimen imaging, and focuses on enhancing the predictability of surgery-based treatments, through innovations in intraoperative imaging. Xeos’ vision is to be a global technology and knowledge leader that provides surgeons, pathologists and other healthcare professionals absolute surgical confidence, and giving their patients instant peace of mind.
The company has a strong track record of in-house PET & CT design. XEOS is an ISO 13485 certified company.
Activities and description
Xeos developed the first-ever PET-CT specimen imager for the operating room, offering surgeons and imaging specialists the sensitivity of PET imaging at submillimeter spatial resolution. Thanks to this mobile scanner, a resected specimen does no longer need to be transported to the radiology or pathology department during surgery. High-quality specimen images can now be obtained in the OR within 10 minutes after excision.
Xeos’ target market is specimen imaging for a diverse range of surgical oncology procedures like breast conserving surgery, prostate cancer and head & neck cancer surgeries.
Xeos is involved in a growing amount of Investigator Initiated Trials with leading Academic Hospital & Institutes across Europe and United States.